LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
The South African on MSN
The HIV-prevention jab is here: What you need to know…
You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback